MAP2K7 and neoplasm: All selected tumor lines (TCG2, TCG3, and TCG4) were characterized by high basal phospho-EGFR expression, along with phospho-AKT and phospho-MEK overexpression, supporting the activation of the EGFR signaling pathway in tumors.